Sponsor Overview
Explore verified public information about Venatorx Pharmaceuticals, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Venatorx will consider requests so that patients with an immediately life-threatening condition or serious disease or condition who have exhausted other appropriate treatment options may, under the conditions described below and in accordance with applicable local law, have appropriate access to its investigational medicines in development before they are commercially available.”
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Venatorx Pharmaceuticals (the “Company”) is focused on conducting clinical studies and obtaining regulatory approval of investigational medicines in support of its mission to develop safe and effective treatments for infectious diseases. The best way for patients to get access to investigational medicines is by taking part in clinical trials. Please search ClinicalTrials.gov for publicly available information related to Venatorx’s ongoing clinical trials. It is recognized that not all patients are eligible to enroll in clinical trials. However, at this time, Venatorx is not able to offer Expanded Access (“EA”) and will not accept EA requests. Venatorx recognizes the need for EA programs. The Company is currently establishing the necessary processes and procedures, as well as putting in place resources and supplies so that an EA program may be established in the future. If you have questions about Venatorx’s EA policy, please contact medinfo@venatorx.com . Available Therapies via Single-Patient EA Cefepime/VNRX-5133 (taniborbactam)
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.